文献速递淋巴瘤

一种CD19/CD3双特异性抗体在伊布替尼时代对慢性淋巴细胞白血病实现有效免疫治疗

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
PubMed 文献 · Blood · 2018-05-09

研究开发了半衰期约5天的单链Fv-Fc格式CD19/CD3双特异性抗体(CD19/CD3-scFv-Fc),在体外和患者来源异种移植小鼠模型中,每周一次给药可清除>98%的初治慢性淋巴细胞白血病(CLL)细胞,而贝林妥欧单抗即使每日给药也未能诱导应答。该抗体对伊布替尼治疗患者及携带BTK和/或PLCG2突变的伊布替尼耐药患者的CLL细胞也有强效活性。

要点

  • CD19/CD3-scFv-Fc半衰期约5天,每周一次给药在小鼠模型中清除>98%的初治CLL细胞。
  • 贝林妥欧单抗即使每日给药也未能诱导应答,而CD19/CD3-scFv-Fc每周一次有效。
  • CD19/CD3-scFv-Fc对伊布替尼耐药(BTK和/或PLCG2突变)CLL细胞在体外和体内均有强效活性。

核心结论

  • 这些数据支持研究CD19/CD3双特异性抗体和其他T细胞募集双特异性抗体作为CLL的免疫治疗,尤其是与伊布替尼联合或作为伊布替尼耐药疾病的挽救治疗。

研究设计与样本

  • 研究开发了单链Fv-Fc格式的CD19/CD3双特异性抗体(CD19/CD3-scFv-Fc),半衰期约5天,并在体外实验和NOD/SCID/IL2Rγnull患者来源异种移植小鼠模型中进行评估。

主要发现

  • 体外实验中,CD19/CD3-scFv-Fc和贝林妥欧单抗均诱导>90%的初治患者CLL细胞杀伤,抗白血病活性与自体CD8和CD4 T细胞增殖、活化及颗粒酶B表达增加相关。
  • 在NOD/SCID/IL2Rγnull患者来源异种移植小鼠模型中,每周一次CD19/CD3-scFv-Fc治疗清除了血液和脾脏中>98%的初治CLL细胞,而贝林妥欧单抗即使每日给药也未能诱导应答。
  • CD19/CD3-scFv-Fc对伊布替尼治疗患者的CLL细胞的杀伤比初治患者更快速。
  • CD19/CD3-scFv-Fc在体外和患者来源异种移植模型中,对携带BTK和/或PLCG2突变的获得性伊布替尼耐药患者的CLL细胞也显示出强效活性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Bruton tyrosine kinase inhibitor ibrutinib induces high rates of clinical response in chronic lymphocytic leukemia (CLL). However, there remains a need for adjunct treatments to deepen response and to overcome drug resistance. Blinatumomab, a CD19/CD3 bispecific antibody (bsAb) designed in the BiTE (bispecific T-cell engager) format, is approved by the US Food and Drug Administration for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Because of its short half-life of 2.1 hours, blinatumomab requires continuous intravenous dosing for efficacy. We developed a novel CD19/CD3 bsAb in the single-chain Fv-Fc format (CD19/CD3-scFv-Fc) with a half-life of ∼5 days. In in vitro experiments, both CD19/CD3-scFv-Fc and blinatumomab induced >90% killing of CLL cells from treatment-naïve patients. Antileukemic activity was associated with increased autologous CD8 and CD4 T-cell proliferation, activation, and granzyme B expression. In the NOD/SCID/IL2Rγnull patient-derived xenograft mouse model, once-weekly treatment with CD19/CD3-scFv-Fc eliminated >98% of treatment-naïve CLL cells in blood and spleen. By contrast, blinatumomab failed to induce a response, even when administered daily. We next explored the activity of CD19/CD3-scFv-Fc in the context of ibrutinib treatment and ibrutinib resistance. CD19/CD3-scFv-Fc induced more rapid killing of CLL cells from ibrutinib-treated patients than those from treatment-naïve patients. CD19/CD3-scFv-Fc also demonstrated potent activity against CLL cells from patients with acquired ibrutinib-resistance harboring BTK and/or PLCG2 mutations in vitro and in vivo using patient-derived xenograft models. Taken together, these data support investigation of CD19/CD3 bsAb's and other T cell-recruiting bsAb's as immunotherapies for CLL, especially in combination with ibrutinib or as rescue therapy in ibrutinib-resistant disease.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Robinson HR, Qi J, Cook EM, et al. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. Blood. 2018. PMID: 29743179. doi:10.1182/blood-2018-02-830992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。